Premium
Successful treatment of Langerhans cell histiocytosis with 2‐chlorodeoxyadenosine
Author(s) -
GOH Nicole S. L.,
MCDONALD Christine F.,
MACGREGOR Duncan P.,
PRETTO Jeffrey J.,
BRODIE Graeme N.
Publication year - 2003
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1046/j.1440-1843.2003.00427.x
Subject(s) - langerhans cell histiocytosis , medicine , chemotherapy , histiocytosis , respiratory failure , disease , pathology
Langerhans cell histiocytosis (LCH) is a rare disorder which frequently involves the lungs of affected adults. Recent evidence suggests it is a clonal neoplastic disorder. Prognosis in this disease is variable, but in its multisystem form or when associated with progressive respiratory dysfunction, prognosis is poor. Recent case reports and a phase II trial of the antimonocyte drug 2‐chlorodeoxyadenosine (2CDA) have described success in treating LCH. We used 2CDA to treat a young Australian man with LCH involving lungs and bone. A complete symptomatic remission was achieved with no evidence of recurrence some 5 years after completion of chemotherapy.